Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for global professionals · Sunday, June 24, 2018 · 452,926,431 Articles · 3+ Million Readers

Amarantus BioSciences CEO , 'The Stock Radio' from Wall Street 1-2-1 , Orlando, Florida

/EINPresswire.com/ SUNNYVALE, CA - May 30, 2012 - Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments for brain-related disorders including Parkinson's disease and traumatic brain injury (TBI) based on its proprietary anti-apoptotic therapeutic protein known as MANF, today released a radio interview of its President & CEO Gerald Commissiong conducted while at the WallStreet121 Conference on TheStockRadio.com. The interview can be viewed at http://thestockradio.com/wp-content/uploads/2012/02/AMBS.mp3.

The StockRadio.com is a small-cap research and investment commentary provider. TheStockRadio.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on TheStockRadio please visit http://thestockradio.com

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for human disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions. For further information please visit www.amarantus.com.

TheStockRadio.com Disclosure

TheStockRadio.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. TheStockRadio.com is a Web site wholly owned by Allan James Group. TheStockRadio.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, TheStockRadio.com, for complete risks and disclosures. Contact: info@theStockRadio.com

Seraphim Strategies
Lou Levenstein
727.489.9939
www.seraphimstrategies.com
www.tomorrowsbluechips.com


Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.
Powered by EIN Presswire